A Phase 2 interventional study of Vascana (0.9% nitroglycerin cream) and Vehicle Cream (placebo) in Raynaud's Phenomenon Secondary to Connective Tissue Disease, sponsored by Covis Pharma S.à.r.l.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-02.
Sponsored by Covis Pharma S.à.r.l. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Connective Tissue Diseases with a site in United States — 17 open to participants now, 27 under way, 12 of them phase 3. Connective Tissue Diseases · United States.
Among the 95 studies in Connective Tissue Diseases with a site in United States, this one is the 35th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2016, is one of 24 in phase 2, and was the 53rd registered.
192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.
Browse Connective Tissue Diseases studies →17 of the 95 studies in Connective Tissue Diseases with a site in United States are open now. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Vericel Corporation · Sites in United States
Ages 17–65
Brigham and Women's Hospital · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
GlaxoSmithKline · Sites in United States, Argentina, Australia and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 27 · Phase 3 21 · Phase 4 5
First in 1979; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 58 across 132 interventional studies indexed under Connective Tissue Diseases.
Median enrollment 67 across the 68 interventional studies, 180 across the 25 observational. Of the 61 that completed or were terminated, 20 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 95 have an industry lead sponsor. The 10 most frequent:
Covis Pharma S.à.r.l. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Covis Pharma S.à.r.l. has 1 study filed under Connective Tissue Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Connective Tissue Diseases with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT06104228Bastiaan Driehuys129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) | 2027-01-01 |
| NCT02234388Hospital for Special Surgery, New YorkUndifferentiated Connective Tissue Disease Registry | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 95 studies in Connective Tissue Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon. The symptoms of this disease include pain, tingling, and numbness in the fingers of the affected hand or hands.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream
Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)
Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vehicle cream, Vascana® (0.9% nitroglycerin cream)
Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)
Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vehicle cream, Vascana® (0.9% nitroglycerin cream)
Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)
Vehicle cream, Vascana® (0.9% nitroglycerin cream), Vascana® (0.9% nitroglycerin cream), Vehicle cream
Drug: Vascana (0.9% nitroglycerin cream) · Drug: Vehicle Cream (placebo)
Study drug administered topically
Vehicle administered topically
Raynaud's Symptom Severity (Change From Baseline)
Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom.
Time frame: 6 weeks
Raynaud's Symptom Severity (Percentage of Responders)
Time frame: 6 weeks
| Milestone | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C | Treatment Sequence D |
|---|---|---|---|---|
| Started | 16 | 16 | 17 | 16 |
| Completed | 16 | 16 | 17 | 16 |
| Not completed | 0 | 0 | 0 | 0 |
Change from baseline to visit 6 in peak Main Raynaud's Symptom (MRS) severity. Raynaud's symptoms will be assessed separately using a 0 to100-mm Visual Analog Scale (VAS) for pain, numbness, and tingling where 0 mm = no symptom and 100 mm = most severe symptom.
| score on a scale | Vascana | Vehicle Cream |
|---|---|---|
| Raynaud's Symptom Severity (Change From Baseline) | -20.19 (-26.63 to -13.75) | -18.63 (-25.07 to -12.19) |
| Participants | Vascana | Vehicle Cream |
|---|---|---|
| Raynaud's Symptom Severity (Percentage of Responders) | 37 | 29 |
Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vascana | 0/65 (0%) | 17/65 (26.2%) | 1/17 (5.9%) |
| Vehicle Cream | 0/65 (0%) | 16/65 (24.6%) | 3/16 (18.8%) |
| Event | Vascana | Vehicle Cream |
|---|---|---|
| Blood Pressure IncreasedVascular disorders | 8/65 | 7/65 |
| Nervous System DisordersNervous system disorders | 1/65 | 4/65 |
| General disorders and administration site conditionsGeneral disorders | 3/65 | 1/65 |
| HypertensionVascular disorders | 1/65 | 3/65 |
| Infections and infestationsInfections and infestations | 2/65 | 1/65 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 2/65 | 0/65 |
| Event | Vascana | Vehicle Cream |
|---|---|---|
| Blood Pressure IncreasedVascular disorders | 1/17 | 2/16 |
| HypertensionVascular disorders | 0/17 | 1/16 |
| Age, Continuous(years) | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C | Treatment Sequence D | Total |
|---|---|---|---|---|---|
| Mean | 52.3 ± 13.37 | 53.8 ± 11.42 | 52.1 ± 16.24 | 47.7 ± 13.34 | 51.4 ± 13.61 |
| Sex: Female, Male(Participants) | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C | Treatment Sequence D | Total |
|---|---|---|---|---|---|
| Female | 14 | 15 | 16 | 15 | 60 |
| Male | 2 | 1 | 1 | 1 | 5 |
| Region of Enrollment(participants) | Treatment Sequence A | Treatment Sequence B | Treatment Sequence C | Treatment Sequence D | Total |
|---|---|---|---|---|---|
| United States | 16 | 16 | 17 | 16 | 65 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jun 2016, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2022, 5 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitroglycerin
Covis Pharma S.à.r.l.